Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

OPT - Opthea Limited - ADR


Previous close
3.03
0   0%

Share volume: 7,020
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.03
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
7.51%
1 Month
38.99%
3 Months
9.03%
6 Months
-14.53%
1 Year
34.16%
2 Year
-50.63%
Key data
Stock price
$3.03
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.60 - $4.40
52 WEEK CHANGE
$0.33
MARKET CAP 
474.833 M
YIELD 
N/A
SHARES OUTSTANDING 
153.887 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,799
AVERAGE 30 VOLUME 
$12,688
Company detail
CEO: Megan Baldwin
Region: US
Website: http://www.opthea.com
Employees: 23
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com

Recent news